Novastep
Private Company
Funding information not available
Overview
Novastep is a private, commercial-stage medical device company targeting the foot and ankle surgery market, specifically hallux valgus (bunion) correction. Its core strategy is to introduce disruptive, minimally invasive surgical (MIS) technologies that offer surgeons greater predictability, accuracy, and control compared to traditional open techniques. The company has a portfolio of commercial products, including the Pecaplasty System for percutaneous bunion correction and the Centrolock Guided Transverse Osteotomy System, and emphasizes economic value for ambulatory surgery centers. As an early-revenue company, Novastep is focused on commercial execution and technological innovation within a large and established orthopedic segment.
Technology Platform
A platform of engineered instrumentation and implant systems for minimally invasive foot and ankle surgery, focusing on guided instrumentation for reproducible osteotomies and proprietary implant designs for stable fixation.
Opportunities
Risk Factors
Competitive Landscape
Novastep competes in the crowded foot and ankle orthopedic device market against giants like Stryker, Zimmer Biomet, and Arthrex, as well as other specialized players. Its differentiation is a focused portfolio on minimally invasive bunion correction with an emphasis on instrumented reproducibility and economic value for ASCs, a niche where larger companies may be less agile.